Does digital IHC need digital tissue controls?

Similar documents
Education 2012 m. Vilnius University, National Cancer Institute, PhD studies 1995 m. Vilnius University, Faculty of Natural Sciences, Master s degree

Image analysis in IHC overview, considerations and applications

Abstract. Background. Objective

Next generation image analysis for immunohistochemistry quantitation

Next-Gen Analytics in Digital Pathology

Layered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue

Interpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment. Lorcan Sherry, CSO OracleBio

Automatic analysis of virtual slides to help in the determination of well established prognostic parameters in breast carcinomas

COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME

Visual interpretation in pathology

Virtual Microscopy: Express Surgical Pathology Consultation. Mercè Jordà, University of Miami, Florida

HER2 ISH (BRISH or FISH)

How to Best Prepare for Digital Pathology: A Primer on Technologies, Applications, and Clinical Contributions. Disclosures

Supplementary Online Content

Central Pathology Review and Tissue MicroArrays. Dr Lisa Storer Children s Brain Tumour Research Centre Nottingham

LOCAL INFLAMMATION IN BREAST TISSUE AND MAMMOGRAPHIC DENSITY AMONG PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN

Digital Pathology and CAP Guidelines

Immune Cell Phenotyping in Solid Tumors using Quantitative Pathology

The following slides were presented at the TIGA Workshop, and are enclosed in the PP show format (*.pps) in order to include all presented details.

Developing quantitative slide-based assays to assess target inhibition in oncology drug discovery and development

Quality assurance and quality control in pathology in breast disease centers

Deciphering the biology that drives response to immunotherapy

Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?

Diagnostics Assessment Report commissioned by the NIHR HTA Programme on behalf of the National Institute for Health and Care Excellence

NordiQC External Quality Assurance in Immunohistochemistry

Incorporating pharmacodynamic, response and patient selection biomarkers. Paul Elvin PhD Chief Translational Science Officer Aptus Clinical

Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry

Gaining New Insights Through IF Multiplexed Staining and Analysis. Tyna Hope, Ph.D. P.Eng Biomarker Imaging Research Laboratory October 5, 2017

Statistical Analysis of Biomarker Data

LN04 - Lymphoma Tissue Microarray

Assessment Run B HER2 IHC

Lessons learned in the use of digital imaging at Memorial Sloan Kettering Cancer Center

Understanding your biomarker: what this marker can do for you

Automated image analysis in the study of lymphocyte subpopulation in eosinophilic oesophagitis

Supplementary Online Content

Data Mining for Research and Diagnostics

Digital Pathology - moving on after implementation. Catarina Eloy, MD, PhD

Assessment Run B HER2 IHC

Product Introduction

CC01 - Colon Cancer Tissue Microarray

Assessment Run GATA3

Digital Pathology Diagnosis Assistance System

manifestations of disease (mostly clinical medicine)

Interobserver Variability of Ki-67 Measurement in Breast Cancer

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Use of tissue micro array (TMA) in routine clinical analysis

Tissue microarray TMA

FAQs for UK Pathology Departments

ARTIFICIAL INTELLIGENCE FOR DIGITAL PATHOLOGY. Kyunghyun Paeng, Co-founder and Research Scientist, Lunit Inc.

Assessment Run B HER-2 IHC. HER-2/chr17 ratio**

Spatially resolved multiparametric single cell analysis. Technical Journal Club 19th September 2017 Christina Müller (Group Speck)

Interpretation guide. Abnormal cytology can t hide anymore

# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer

(A) PCR primers (arrows) designed to distinguish wild type (P1+P2), targeted (P1+P2) and excised (P1+P3)14-

Molecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue.

Optimal algorithm for HER2 testing

Breast cancer: Antibody selection, protocol optimzation controls and EQA

Definiens. Tissue Studio 4.2. Tutorial 8: Cell Simulation and Classification

Multiplex immunofluorescence for investigating the prognostic value of immune cells Chidozie Anyaegbu, PhD

Is digital pathology ready for use in routine histopathology? Dr David Snead University Hospitals of Coventry and Warwickshire NHS Trust Coventry UK

Tumor Growth Rate (TGR) A New Indicator of Antitumor Activity in NETS? IPSEN NET Masterclass Athens, 12 th November 2016

CINtec PLUS Cytology. Interpretation training

CHEK Proficiency study 672. Phthalates in nail polish. Date 5 December 2017 Version 1. Report number CHEK

Positive Results on Fecal Blood Tests

CENTRAL LABORATORY SERVICES

Molecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue.

Product Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue

Quality Assurance and Quality Control in the Pathology Dept.

Applying Tissue Phenomics to Colorectal Clinical Questions

Background Information

Results you can trust

Analysis of Immunohistochemical Stain Usage in Different Pathology Practice Settings

Application of tissue microarrays for receptor immunohistochemistry in breast carcinoma

Welcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016

PROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT

Comparison of evaluations of hormone receptors in breast carcinoma by image-analysis using three automated immunohistochemical stainings

IHC Stainer platforms. Overview, pros and cons

P16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future.

Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we

Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma

Supplementary Appendix

Aida Laurinaviciene 1,2*, Darius Dasevicius 2,3, Valerijus Ostapenko 1, Sonata Jarmalaite 4, Juozas Lazutka 4 and Arvydas Laurinavicius 2,3.

CME/SAM. Software-Automated Counting of Ki-67 Proliferation Index Correlates With Pathologic Grade and Disease Progression of Follicular Lymphomas

IDH1 R132H/ATRX Immunohistochemical validation

Inti Zlobec 1*, Viktor H Koelzer 1,2, Heather Dawson 1,2, Aurel Perren 1,2 and Alessandro Lugli 1,2

Expanded View Figures

Dr. dr. Primariadewi R, SpPA(K)

Detection Of Red Lesion In Diabetic Retinopathy Using Adaptive Thresholding Method

Measuring cell density in prostate cancer imaging as an input for radiotherapy treatment planning

UCL-Advanced Diagnostics. 2015/16 Service Update

Pathfinder Holter Analyzer CARDIAC DIAGNOSTIC SOLUTIONS

Classification of electrocardiographic ST-T segments human expert vs artificial neural network

Utilization of Virtual Microscopy in a Cooperative Group Setting

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

ANALYTISCHE STRATEGIE Tissue Imaging. Bernd Bodenmiller Institute of Molecular Life Sciences University of Zurich

Immunotherapy in NSCLC Pathologist role

Identification of Sickle Cells using Digital Image Processing. Academic Year Annexure I

Transcription:

VILNIUS UNIVERSITY Digital immunohistochemistry platform for the staining variation monitoring based on integration of image and statistical analyses with laboratory information system Arvydas Laurinavicius 12th European Congress on Digital Pathology Paris, France, 18-21 June 2014

Does digital IHC need digital tissue controls? Conventional IHC staining quality is monitored by semiquantitative visual evaluation of tissue (multi)controls Image analysis may require more sensitive quality control Intra- and interlaboratory IHC staining variation may be a major obstacle for DIA adoption We have previously shown intra-laboratory HER2 IHC variation by digital analysis means

HER2 average membrane staining intensity variation 0 1+ 0 1+ 2+ 2+ Batch/Serial section # 3+ 3+ Laurinavicius, Besusparis, et al Diagnostic Pathology 2013.

Integrated IHC staining monitor by and for digital analysis Explore Ki67 IHC staining variation in our laboratory routine, set up LIS integration of the IHC tissue multi-controls, monitored by image analysis, and supported by automated statistical analysis feedback

Consecutive sections (n=69) of one TMA block containing 10 cores of breast cancer tissue used as tissue controls in routine Ki67 IHC testing Ventana slide label BarcodeID was sent to the LIS to register the serial section sequence, then used for statistical analyses Slides stained and scanned (Aperio ScanScope XT), IA performed by the Aperio/Leica Colocalization and Genie Classifier/Nuclear algorithms SQL-based SpectrumPlus/LIS integration ensured automated statistical analysis of the IA data by the SAS Enterprise Guide project Factor analysis and plot visualizations to explore slide-to-slide variation of the Ki67 IHC staining results in the control tissue

Workflow TMA block with 10 control tissue cores Serial sections stored at +4C Used on demand for routine Ki67 TMALAB design applied for the tissue controls Slides stained and scanned Ventana BarcodeID stored in LIS when slide label printed Colocalization Genie/Nuclear performed on the TMA and WSI SAS project rerun from the Spectrum/LIS SQL query Statistical feedback generated

Intraslide Intertissue Intraslide Intertissue

4 8 3 7 2 6 10 1 5 9 Variation of individual 10 spots

Slide-to-slide variation of the TMA multicontrols Total Nuclei Total Stained Area (mm2) Positive Nuclei Brown Intensity The sequence of Ventana slide Barcode on the x axis to represent consecutive serial sections of TMA blocks of the 10 multi-tissue control cores (labelled as SampleID),

Slide-to-slide variation of the TMA multicontrols Percent Positive Nuclei Blue Intensity Positive Density (Pos Nuclei/mm 2 ) Brown/Blue Intensity ratio The sequence of Ventana slide Barcode on the x axis to represent consecutive serial sections of TMA blocks of the 10 multi-tissue control cores (labelled as SampleID),

Factor pattern of Brown and Blue intensity indicators from Colocalization Analysis in 10 individual TMA cores Total Intensity Both Brown and Blue lighter Relatively deeper Blue Brown/Blue balance

4 8 3 2 7 6 10 e.g., Sum (Area) Sum (Total Nuclei) Median (Intensity) etc. 1 5 9 Variation of aggregated data from the 10 TMA spot images super-multi-tissue control

Factor pattern of Colocalization and Genie/Nuclear analysis outputs aggregated from 10 TMA cores IHC positivity High Ki67 LI, Dark Brown More tissue, Dark Blue Amount of Tissue Detected with Darker Blue

Relevant inverse covariation of selected image analysis variables Median Blue Intensity (Colocalization) Area of Analysis (Genie) Aggregated data from 10 TMA cores plotted against the sequence of Ventana Barcode on the x axis

The solution enabled continuous monitor of IHC multi-tissue controls by the means of IA, followed by automated statistical analysis, integrated into the laboratory workflow. Even in consecutive serial tissue sections, tissue-related factors affected the IHC IA results; meanwhile, less intense blue counterstain was associated with less amount of tissue, detected by the IA tools.

Remarks Scanning variation was not addressed in our experiment, same scanner used. The IA issues with hematoxylin counterstain in IHC, have been highlighted, alternative counterstaining and IA techniques have been proposed Brey at al J Histochem Cytochem 2003, Pham et al Diagn Pathol 2007, Stefanovic et albiotechnic & histochemistry 2013, Zehntner et al J Histochem Cytochem 2008, Bernardo et al Microsc Microanal 2009] Another approach - measuring signal-to-noise ratio of the images to evaluate quality before IA (Ali et al Br J Cancer 2013), however, adjustment of the images and/or analyses may require effort. Our data simulate reproducibility of the Ki67 index in the consecutive sections of one 1 mm diameter core: variation of Ki67% (the IA result) was satisfactory (standard deviation in all 10 cores ranged from 3 to 8, relative error within the range of 0.07 to 0.39) the variation of cell numbers detected (the process) was higher. Inter-laboratory IHC staining variation is likely to be more significant: international Ki67 reproducibility study (Polley et al J Natl Cancer Inst 2013) revealed unsatisfactory results of visual estimation which was even worse when the slides were stained locally. Further optimization and standardization of IHC procedures, especially, when applying IA tools with unknown sensitivity to the staining/scanning variation. Ideally, IA tools should be robust and resistant to the IHC staining and scanning variations.

Aida Laurinavičienė and Paulette Herlin Daiva Lesciute- Krilaviciene Yasir Iqbal Benoit Plancoulaine Darius Raudeliunas Raimundas Meškauskas Indra Baltrušaitytė, Justinas Besusparis A COMPREHENSIVE BIOMARKER INTRA- TUMOUR HETEROGENEITY EVALUATION BY DIGITAL IMMUNOHISTOCHEMISTRY IMAGE ANALYSIS This research is funded by European Social Fund under the Global Grant measure.

www.vpc.lt